At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Tazarotene Lotion, 0.1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
In Brief
A Phase 2 clinical trial evaluating Tazarotene Lotion, 0.1% and Tazarotene Cream, 0.1% for Acne Vulgaris. Completed, enrolled 58 participants across 2 sites.
Detailed Summary
This was a multicenter, randomized, multiple-dose, laboratory-blinded, open-label, 2-arm, parallel-arm study in subjects with moderate acne vulgaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
Primary CompletionApr 2018
First PostedJul 2018
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartOct 4, 2017
Primary CompletionApr 30, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago
Interventions
Tazarotene Lotion, 0.1%drug
DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
Tazarotene Cream, 0.1%drug
Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours